Specifically, the knockdown of DLGAP5 not only significantly inhibited the proliferation and invasion of colorectal, clear cell renal cell carcinoma, hepatocellular carcinoma, and pancreatic cancer cells but also induced cell cycle arrest in ovarian and breast cancer cells [15–20]. Here, DLGAP5 is linked to breast carcinoma.